ClinicalTrials.gg
CompletedNCT03877224Updated Nov 17, 2021Results posted

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

A Phase 3 interventional study of Dapagliflozin and Placebo in Heart Failure With Preserved Ejection Fraction (HFpEF), sponsored by AstraZeneca. Completed at 101 sites in 12 countries. Open to participants aged 40 Years to 150 Years. Per ClinicalTrials.gov, last updated 2021-11-17.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
40 Years to 150 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.

Enrollment
11th of 59
504 · median 100
Started
2019
with 2 others
Phase 3
16 of 59
5 open now
Registered
6th of 59
by date
Lead sponsor
7 of 59
AstraZeneca

Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 11th largest by enrollment, is one of 3 that started in 2019, is one of 16 in phase 3, and was the 6th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 40 Years to 150 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing dapagliflozin in Heart Failure, or all of them as a file.
02

Study summary

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF)

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction (HFpEF)

Browse trials for

04

Who can participate

Ages eligible
40 Years to 150 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed prior to any study specific procedures
  • Male or female, aged ≥40 years
  • Established documented diagnosis of symptomatic HFpEF ( functional class II-IV), which has been present for at least 8 weeks
  • >40% and evidence of structural heart disease
  • Elevated NT-proBNP levels
  • Patients should receive background standard of care as described below: All patients will be treated according to locally recognised guidelines on standard of care treatment for patients with HFpEF. Therapy should have been individually optimised and stable for ≥4 weeks (this does not apply to diuretics) and include (unless or not tolerated) treatment of co morbidities (including high blood pressure, ischaemic heart disease, atrial fibrillation/flutter).
  • 6MWD≥100 metres and ≤425 metres at enrolment and randomization

Exclusion criteria

Exclusion Criteria:

  • Presence of any condition that precludes exercise testing
  • Participation in a structured exercise training programme in the 1 month prior to screening or planned to start during the trial
  • Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
  • Type 1 diabetes mellitus
  • \<25 mL/min/1.73 m2 (CKD-EPI formula) at enrolment, unstable or rapidly progressing renal disease at time of randomisation
  • Systolic BP \<95 mmHg on 2 consecutive measurements
  • Systolic BP ≥160 mmHg if not on treatment with ≥3 blood pressure lowering medications or ≥180 mmHg irrespective of treatments, on 2 consecutive measurements
  • Current acute decompensated HF or hospitalisation due to decompensated HF \<4 weeks prior to enrolment
  • MI, unstable angina, coronary revascularization ablation of atrial fibrillation/flutter, valve repair/replacement, implantation of a cardiac resynchronization therapy device within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization.
  • Stroke or within 12 weeks prior to enrolment.
  • Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including .
  • Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization
  • HF due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia, or uncorrected primary valvular disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
504 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    Green, diamond shaped, film coated tablets 10 mg administered orally, once daily

    Drug: Dapagliflozin

  • Placebo comparator
    Placebo

    Green, diamond shaped, film coated tablets placebo administered orally, once daily

    Other: Placebo

Interventions

  • Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.

  • OtherPlacebo

    Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)

    Change from baseline in KCCQ-TSS was defined as the endpoint value at week 16 minus the baseline value. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ-TSS incorporates symptom frequency (4 items) and symptom burden (3 items) domains into a single score. The score is transformed to a range of 0-100 (higher score reflects better health status). Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants alive at the week 16 visit but without KCCQ-TSS values. All the data for the endpoint, except for death, collected during COVID-19, are set as missing and imputed same way as pre-COVID-19 missing data.

    Time frame: At baseline and at week 16 or death before week 16

  2. Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) at Week 16 (Higher Scores Represent Less Physical Limitation Due to HF)

    Change from baseline in KCCQ-PLS was defined as the endpoint value at week 16 minus the baseline value. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ-PLS incorporates 6 physical limitation items into a single score. The score is transformed to a range of 0-100 (higher score reflects better health status). Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants who were alive at week 16 visit but without KCCQ-PLS values. All the data for the endpoint, except for death, collected during COVID-19, are set as missing and imputed same way as pre-COVID-19 missing data.

    Time frame: At baseline and at week 16 or death before week 16

  3. Change From Baseline in 6-minute Walk Distance (6MWD) at Week 16 (Larger Distances Represent Better Functional Capacity)

    Change from baseline in 6-minute walk distance (6MWD) (exercise capacity) at week 16 was defined as the distance walked in 6 minutes at week 16 minus the baseline value. Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants who were alive at the visit at week 16 but did not have 6MWD values.

    Time frame: At baseline and at week 16 or death before week 16

Secondary outcomes

  1. Change From Baseline at the End of the Study in the Total Time Spent in Light to Vigorous Physical Activity, as Assessed Using a Wearable Activity Monitor (Accelerometer).

    Change from baseline at the end of the study in total time spent in light to vigorous physical activity (LVPA), as assessed using a wearable activity monitor, was defined as the total time \[per day\] spent in LVPA at the end of the study minus the baseline value. Baseline is the 7 day period starting on the day of enrolment and ending before randomization. End of study is defined as the period starting on the day of week 14 and prior to the week 16 visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive.

    Time frame: At baseline and at end of study or death before week 16.

07

Results

Posted Nov 17, 2021
Limitations and caveats
In this study, a subset of participants received wearable activity monitors to wear at home for 3 periods of 7 days. Data collection from the wearable device was challenging and a substantial amount of data was missing. This limits the use of the data based on the wearable activity monitors to investigate the potential impact of study drug on the amount, duration, and intensity of physical activity.

Participant flow

Participant flow — Overall Study
MilestoneDapa 10 mgPlacebo
Started253251
Treated252249
Completed248243
Not completed58
Withdrew: Death32
Withdrew: Withdrawal by subject16
Withdrew: Participant is alive, just unable to come for visits10

Outcome measures

PrimaryChange From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)

Change from baseline in KCCQ-TSS was defined as the endpoint value at week 16 minus the baseline value. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ-TSS incorporates symptom frequency (4 items) and symptom burden (3 items) domains into a single score. The score is transformed to a range of 0-100 (higher score reflects better health status). Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants alive at the week 16 visit but without KCCQ-TSS values. All the data for the endpoint, except for death, collected during COVID-19, are set as missing and imputed same way as pre-COVID-19 missing data.

Time frame:
At baseline and at week 16 or death before week 16
Reported as:
Median · Score on a scale
Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)
Score on a scaleDapa 10mgPlacebo
Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)5.21 (-3.13 to 12.50)1.04 (-5.73 to 15.10)
Statistical analysis
  • Dapa 10mg vs Placebo · Rank ANCOVA · p = 0.07905 (To account for multiplicity, a pre-specified testing strategy was followed to control the overall type I error rate.) · Hodges-lehmann median diff. vs placebo: 3.16 · 95% CI 0.36 to 6.01The model includes rank-based baseline, weeks impacted by COVID-19 and treatment group as covariates and is stratified by T2DM status at randomization
PrimaryChange From Baseline in Kansas-City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) at Week 16 (Higher Scores Represent Less Physical Limitation Due to HF)

Change from baseline in KCCQ-PLS was defined as the endpoint value at week 16 minus the baseline value. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ-PLS incorporates 6 physical limitation items into a single score. The score is transformed to a range of 0-100 (higher score reflects better health status). Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants who were alive at week 16 visit but without KCCQ-PLS values. All the data for the endpoint, except for death, collected during COVID-19, are set as missing and imputed same way as pre-COVID-19 missing data.

Time frame:
At baseline and at week 16 or death before week 16
Reported as:
Median · Score on a scale
Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) at Week 16 (Higher Scores Represent Less Physical Limitation Due to HF)
Score on a scaleDapa 10mgPlacebo
Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) at Week 16 (Higher Scores Represent Less Physical Limitation Due to HF)0.00 (-4.17 to 12.50)0.00 (-8.33 to 12.50)
Statistical analysis
  • Dapa 10mg vs Placebo · Rank ANCOVA · p = 0.23215 (To account for multiplicity, a pre-specified testing strategy was followed to control the overall type I error rate.) · Hodges-lehmann median diff. vs placebo: 3.12 · 95% CI -0.09 to 5.37The model includes rank-based baseline, weeks impacted by COVID-19 and treatment group as covariates and is stratified by T2DM status at randomization
PrimaryChange From Baseline in 6-minute Walk Distance (6MWD) at Week 16 (Larger Distances Represent Better Functional Capacity)

Change from baseline in 6-minute walk distance (6MWD) (exercise capacity) at week 16 was defined as the distance walked in 6 minutes at week 16 minus the baseline value. Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants who were alive at the visit at week 16 but did not have 6MWD values.

Time frame:
At baseline and at week 16 or death before week 16
Reported as:
Median · meters
Change From Baseline in 6-minute Walk Distance (6MWD) at Week 16 (Larger Distances Represent Better Functional Capacity)
metersDapa 10mgPlacebo
Change From Baseline in 6-minute Walk Distance (6MWD) at Week 16 (Larger Distances Represent Better Functional Capacity)9.0 (-15.0 to 37.0)8.5 (-14.5 to 35.5)
Statistical analysis
  • Dapa 10mg vs Placebo · Rank ANCOVA · p = 0.66801 (To account for multiplicity, a pre-specified testing strategy was followed to control the overall type I error rate.) · Hodges-lehmann median diff. vs placebo: 1.6 · 95% CI -5.9 to 9.0The model includes rank-based baseline, treatment group as covariates and is stratified by T2DM status at randomization
SecondaryChange From Baseline at the End of the Study in the Total Time Spent in Light to Vigorous Physical Activity, as Assessed Using a Wearable Activity Monitor (Accelerometer).

Change from baseline at the end of the study in total time spent in light to vigorous physical activity (LVPA), as assessed using a wearable activity monitor, was defined as the total time \[per day\] spent in LVPA at the end of the study minus the baseline value. Baseline is the 7 day period starting on the day of enrolment and ending before randomization. End of study is defined as the period starting on the day of week 14 and prior to the week 16 visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive.

Time frame:
At baseline and at end of study or death before week 16.
Reported as:
Median · hours/day
Change From Baseline at the End of the Study in the Total Time Spent in Light to Vigorous Physical Activity, as Assessed Using a Wearable Activity Monitor (Accelerometer).
hours/dayDapa 10mgPlacebo
Change From Baseline at the End of the Study in the Total Time Spent in Light to Vigorous Physical Activity, as Assessed Using a Wearable Activity Monitor (Accelerometer).-0.06 (-0.63 to 0.44)-0.07 (-0.67 to 0.13)
Statistical analysis
  • Dapa 10mg vs Placebo · Rank ANCOVA · p = 0.12523 · Hodges-lehmann median diff. vs placebo: 0.19 · 95% CI -0.06 to 0.48Model includes baseline rank of outcome variable as a covariate, treatment group as a factor, and is stratified by T2DM status at randomization.

Adverse events

Collected over Includes data collected on or after date of first dose and up to (including) 30 days following last dose of randomized study drug, and no later than visit 5 (up to day 119). Deaths collected on or after first dose of randomized study drug, up to 119 days.. Non-serious events are listed at a 0.05% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapa 10 mg3/252 (1.2%)26/252 (10.3%)0/252 (0%)
Placebo2/249 (0.8%)19/249 (7.6%)0/249 (0%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventDapa 10 mgPlacebo
Cardiac failureCardiac disorders2/2524/249
Urinary tract infectionInfections and infestations4/2520/249
PneumoniaInfections and infestations2/2523/249
Cardiac failure acuteCardiac disorders1/2522/249
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2522/249
Atrial fibrillationCardiac disorders2/2521/249
Cardiac failure congestiveCardiac disorders2/2520/249
Skin lacerationInjury, poisoning and procedural complications2/2520/249
EpistaxisRespiratory, thoracic and mediastinal disorders2/2520/249
Acute myocardial infarctionCardiac disorders1/2521/249

Baseline characteristics

Full Analysis Set: All participants that were randomized, regardless of whether treated or not.

Age, Continuous
Age, Continuous(Years)Dapa 10 mgPlaceboTotal
Mean72.0 ± 9.171.7 ± 9.771.8 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Dapa 10 mgPlaceboTotal
Female9193184
Male162158320
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dapa 10 mgPlaceboTotal
Hispanic or Latino283159
Not Hispanic or Latino225220445
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapa 10 mgPlaceboTotal
White192178370
Black or African American171734
Asian365086
Native Hawaiian or other Pacific Islander101
Other7613
American Indian or Alaska Native000
08

Study locations

101 sites
  • Research Site
    Alexander City, Alabama 35010, United States
  • Research Site
    Fort Payne, Alabama 35967, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Jacksonville, Florida 32209, United States
  • Research Site
    Miami, Florida 33133, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Tucker, Georgia 30084, United States
  • Research Site
    Arlington Heights, Illinois 60005, United States
  • Research Site
    Hazel Crest, Illinois 60429, United States
  • Research Site
    Munster, Indiana 46321, United States
  • Research Site
    Louisville, Kentucky 40205, United States
  • Research Site
    Bossier City, Louisiana 71111, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    New Brunswick, New Jersey 08901, United States
  • Research Site
    Ridgewood, New Jersey 07450, United States
  • Research Site
    Rosedale, New York 11422, United States
  • Research Site
    Burlington, North Carolina 27215, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Cincinnati, Ohio 45267, United States
  • Research Site
    Abington, Pennsylvania 19001, United States
  • Research Site
    Doylestown, Pennsylvania 18901, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Spring, Texas 77380, United States
  • Research Site
    Seattle, Washington 98101, United States
  • Research Site
    Caba, C1425AGC, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aire, C1407GTN, Argentina
  • Research Site
    Ciudad Autonomade Buenos Aires, 1426, Argentina
  • Research Site
    Blumenau, 89020-430, Brazil
  • Research Site
    Brasillia, 72145-450, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Sao Paulo, 01141-020, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Plovdiv, 4003, Bulgaria
  • Research Site
    Sofia, 1000, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Veliko Tarnovo, 5000, Bulgaria
  • Research Site
    Edmonton, Alberta T5A 4L8, Canada
  • Research Site
    Moncton, New Brunswick E1G 1A7, Canada
  • Research Site
    Mount Pearl, Newfoundland and Labrador A1N 1W7, Canada
  • Research Site
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Research Site
    Ajax, Ontario L1Z 0B1, Canada
  • Research Site
    Guelph, Ontario N1H 1B1, Canada
  • Research Site
    North York, Ontario M3M 3E5, Canada
  • Research Site
    Scarborough, Ontario M1E 5E9, Canada
  • Research Site
    Scarborough, Ontario M1P 2T7, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Gatineau, Quebec J8Y 6S8, Canada
  • Research Site
    Longueuil, Quebec J4M 2X1, Canada
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
  • Research Site
    Montreal, Quebec H3G 1A4, Canada
  • Research Site
    St-Georges, Quebec G5Y 4T8, Canada
  • Research Site
    Quebec, G1G 3Y8, Canada
  • Research Site
    Quebec, G2J 0C4, Canada
  • Research Site
    Quebec, G3K 2P8, Canada
  • Research Site
    Esbjerg, 6700, Denmark
  • Research Site
    Hellerup, 2900, Denmark
  • Research Site
    Hjørring, 9800, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    København, 2300, Denmark
  • Research Site
    Næstved, 4700, Denmark
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    Randers, 8930, Denmark
  • Research Site
    Svendborg, DK-5700, Denmark
  • Research Site
    Århus N, 8200, Denmark
  • Research Site
    Bergamo, 24127, Italy
  • Research Site
    Milano, 20162, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Palermo, 90127, Italy
  • Research Site
    Roma, 00189, Italy
  • Research Site
    San Giovanni Rotondo, 71013, Italy
  • Research Site
    Akashi-shi, 674-0063, Japan
  • Research Site
    Daito-shi, 574-0074, Japan
  • Research Site
    Kasugai-shi, 487-0016, Japan
  • Research Site
    Matsubara-shi, 580-0032, Japan
  • Research Site
    Naha, 902-8511, Japan
  • Research Site
    Omihachiman-shi, 523-0082, Japan
  • Research Site
    Osaka-shi, 530-0001, Japan
  • Research Site
    Shunan-shi, 745-0822, Japan
  • Research Site
    Takarazuka-shi, 665-0873, Japan
  • Research Site
    Toshima-ku, 171-0014, Japan
  • Research Site
    Gangwon-do, 26426, Korea, Republic of
  • Research Site
    Gwangju, 61469, Korea, Republic of
  • Research Site
    Seongnam-si, 463-707, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Brezno, 97742, Slovakia
  • Research Site
    Lucenec, 984 01, Slovakia
  • Research Site
    Martin, 036 01, Slovakia
  • Research Site
    Presov, 080 01, Slovakia
  • Research Site
    Ruzomberok, 034 26, Slovakia
  • Research Site
    Cape Town, 7500, South Africa
  • Research Site
    Diepkloof, Soweto, 2013, South Africa
  • Research Site
    Pinelands, 7405, South Africa
  • Research Site
    Borås, 506 30, Sweden
  • Research Site
    Göteborg, 413 45, Sweden
  • Research Site
    Lund, 222 21, Sweden
  • Research Site
    Ostersund, 831 83, Sweden
  • Research Site
    Stockholm, 114 46, Sweden
  • Research Site
    Stockholm, 118 83, Sweden

Showing the first 100 of 101 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Jul 2020, 15 months.

Results were first posted in Nov 2021, 1 year 4 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 15 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2019
First posted
Mar 15, 2019
StartActual
Apr 4, 2019
Primary completionActual
Jul 9, 2020
CompletionActual
Jul 9, 2020
Results first posted
Nov 17, 2021
Last update
Nov 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03877224
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Apr 4, 2019
Primary completion
Jul 9, 2020
Completion
Jul 9, 2020
Results posted
Nov 17, 2021
Last update
Nov 17, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion